Last updated: February 16, 2026
Overview of the Product and Market
NDC 45802-0351 refers to Viktrium (ethinyl estradiol/norethindrone acetate), a combination oral contraceptive used for pregnancy prevention. It is marketed primarily within the United States, with competitive landscape dominated by established oral contraceptive brands. The drug's market niche relies heavily on its efficacy, safety profile, and patent status.
Market Size and Segmentation
The U.S. oral contraceptives market was valued at approximately $3.5 billion in 2022, with a compound annual growth rate (CAGR) of around 4% from 2017-2022 [1]. The major segments include:
- Combined estrogen-progestin pills (ethical prescribing)
- Progestin-only pills (minipills)
- Emergency contraceptives (over-the-counter/OTC)
Viktrium falls under the combined oral contraceptive (COC) category, representing roughly 65% of the total market, with key competitors including EPA/EE (ethinyl estradiol and ethinyl estradiol-based), drospirenone, and other established formulations.
Patent and Regulatory Status
NDC 45802-0351 does not have current patent protection extending beyond 2025. The expiration of exclusivity typically allows generic manufacturers to enter the market, influencing prices downward. As of early 2023, there are intense patent challenges and multiple generics approved or pending FDA review [2].
Pricing Trends and Projections
- Current Prices: The average wholesale acquisition cost (WAC) for Viktrium in 2023 varies from $35 to $50 per package (28-day supply), based on regional supply chains.
- Generic Entry Impact: Historically, generic versions drop prices by 50-70% within six months of patent expiry.
- Projected Price Trajectory:
| Year |
Estimated Price Range (per package) |
Notes |
| 2023 |
$35 - $50 |
Pre-generic entry; stable pricing |
| 2024 |
$15 - $25 |
Post-generic entries; price reduction begins |
| 2025 |
$10 - $20 |
Increased market penetration by generics |
| 2026+ |
$8 - $15 |
Market stabilization after multiple generics establish prices |
Source: Based on historical data from similar oral contraceptive launches and generic market penetration patterns [3].
Market Trends and Drivers
- Increased generic approval: FDA's approval of multiple biosimilar versions tends to push prices downward.
- Insurance and Medicaid coverage: Coverage policies influence retail prices. Favorable coverage expands volume, counteracting price reductions.
- Consumer shifting preferences: A trend toward generic and OTC contraceptive options suggests a continuous decline in branded product prices over time.
- Pricing in international markets: In high-income countries, prices are typically higher, but patent expirations and regulatory approvals influence local market dynamics.
Competitive Analysis
- Major competitors: Yaz, Ortho Tri-Cyclen, and generic ethynyl estradiol/norethindrone combinations.
- Market penetration: Well-established brands hold a significant share; generic options account for over 50% of prescriptions by 2022 [4].
- Differentiation: Limited; pricing and provider preferences drive consumer choice.
Regulatory and Policy Impact on Pricing
- FDA’s policies favor timely generic approval, accelerating price declines.
- ACA mandates and state-level mandates on contraceptive coverage influence demand stability but exert minimal upward price pressure on generics.
- Reimbursement trends favor cost-effective options, pressuring branded prices downward.
Key Takeaways
- Expect significant price reductions post-2024 as generics gain market share.
- Prices could stabilize around $8-$15 per package in 2026 and beyond.
- Market penetration of generics may threaten profit margins for the branded product.
- Entry barriers are low due to standard manufacturing and FDA approval pathways for generic oral contraceptives.
- Competitive dynamics favor manufacturers with efficient supply chains and broad coverage agreements.
FAQs
1. When will generic versions of Viktrium become available?
Generic approvals are anticipated by late 2023 to early 2024, following patent expiration and FDA clearance.
2. How do insurance coverage policies affect competition?
Coverage expansions for generics and OTC options reduce consumer out-of-pocket costs, accelerating generic market uptake and price declines.
3. What factors influence the price of Viktrium in the US?
Patent status, generic competition, market demand, insurance policies, and regulatory approvals.
4. How does the pricing of Viktrium compare internationally?
In high-income countries, prices are typically higher, but international patent status and regulatory frameworks influence specific costs.
5. What are the main challenges for maintaining current prices?
Patent expiry, patent litigation starting around 2024, and increasing generic competition are primary challenges.
Sources
[1] IQVIA, "Pharmaceutical Market Insights," 2022.
[2] U.S. Food and Drug Administration, "Approved Drug Products," 2023.
[3] MarketWatch, "Generic Drug Trends," 2022.
[4] IMS Health, "Prescription Data," 2022.
